

## CURRICULUM VITAE

### **LAURENCE A. LASKY**

Latterell Venture Partners  
1 Embarcadero Center  
Suite 4050  
San Francisco, CA 94111

### **PERSONAL INFORMATION**

Cell Phone: 415-987-2337  
email address: larry@lvpcapital.com

### **EDUCATION**

Undergraduate University of California, Los Angeles  
June, 1973 - B.A.  
Majors - Biology and Music  
  
Manhattan School of Music-1971

Graduate University of California, Los Angeles  
Laboratory of Dr. Allan Tobin  
August, 1978 - Ph.D. Biology

Post Graduate California Institute of Technology  
Laboratory of Dr. Eric Davidson  
August, 1978 - April 1981 Postdoctoral Fellow

### **ACADEMIC HONORS**

B.A. cum laude, 1973  
Departmental honors in Biology, 1973  
Physiology Course, Woods Hole Marine Biological Laboratory, 1974  
Teaching Assistant, UCLA Department of Biology, 1974-1976  
USPHS Predoctoral Trainee, 1976-1978  
NIH Postdoctoral Fellow, 1978-1980  
NIH SBIR Biology Study Section 1984  
Member NCI Special Study Section on Retroviral Vaccines - 1986  
Member NCI Special Study Section on Retroviral Neutralization - 1987  
Member NCI Special Study Section on Human Endogenous Retroviruses - 1986  
Member NCI Special Study Section Retroviral Therapeutics - 1987  
Member NCI Special Study Section on AIDS-1988  
Member Editorial Board AIDS Research and Human Retroviruses 1986 - 1990  
Section Editor: Vaccine R and D, AIDS Research and Human Retrovirus 1988 - 1990  
Member, Organizing Committee, International AIDS Conference, Stockholm, Sweden, 1987-1988  
Organizer, UCLA Symposium on Technological Advances in Vaccines Development 1987-1988  
Co-Organizer, Keystone Symposium on the Molecular and Cellular Biology of the Endothelium,  
1991-1992  
Ad Hoc Reviewer: RCMI Special Study Section-1990

Ad Hoc Reviewer: Science, Nature, Cell, J. Clin. Inv., J. Biol. Chem., Cell Regulation, J. Cell Biol., AIDS, J. Acq. Imm. Def. Synd., J. Immunol., AIDS Res. and Hum. Ret., Immunology Today, J. Exp. Med., Am. J. Pathology, Molecular Biology of the Cell, Proceedings of the National Academy of Sciences(USA), Blood, J. Cellular Biochem., Current Biology, Immunity, Am. J. Pathology, J. Immunological Methods, Arteriosclerosis and Thrombosis, Development, Eur. J. Immunol., Cancer Research, British Journal of Cancer, Biochimica et Biophysica Acta, Biochemistry, FEBS Letters, Nature Cell Biology, Oncogene, Molecular Cell, EMBO Journal, Experimental Cell Research, International Journal of Cancer. J. Molecular Biology, Molecular and Cellular Biology, Biochemistry, Apoptosis, J. Cell. Physiol., Nature Reviews Drug Discovery

Executive Member Scientific Advisory Board-Keystone Symposia on Cell and Molecular Biology 1991-2002

Member NIH Parent Review Committee for the Pulmonary SCOR Program 1992-1993

Editorial Board: Genomethods 1993-present

American Men and Women of Science 1994

Who's Who in Science and Engineering 1997

Who's Who in the West 1998

Board of Consulting Editors-The Journal of Clinical Investigation 1998-2002

Venture Capital Consultant: Interwest, Soffinova, J.P. Morgan, Skyline Ventures, Technology Ventures 1999-2002

Reviewing Board, UCSF Biomedical Sciences Training Program 2001

Editorial Board: Current Analytical Chemistry, 2004

## **COMMITTEES, BOARDS etc.**

Co-Chair TENEX Committee on Genomics 2000

Board of the Society of Encouragement of Contemporary Art (SECA) 1998-1999

Board of ZYZZYVA- a West Coast Arts and Literature Magazine 1999-2005

Scientific Advisory Board for IO Pharmaceuticals 2000-2001

Interwest Venture Capital Medical Technology Board 2000-2001

Advisory Board, University of Hawaii Medical School 2003-present

Director, Cell Biosciences, Inc., 2003-2006

Director, Pharmix, Inc., 2004-2006

Director, OncoMed, Inc., 2004-present

Director, Proteolix, Inc., 2003-present

Director, Bayhill Pharmaceuticals, 2005-2006

Director, Bioverdant, Inc., 2006-present

Director, Tetralogic, Inc., 2006-present

Timpanist, Symphony Parnassus, 1999-present

Photography Accessions Committee,

SF MOMA, 2005-present

Consultant, One World Health 2006-present

Associate Member, Bohemian Club 2006-present

## **SOCIETIES**

American Society for Biochemistry and Molecular Biology

American Society for Investigational Pathology

## **POSITIONS HELD**

Senior Scientist -Genetics Institute, 1981-1982

Scientist -Department of Vaccine Development, Genentech, Inc., 1982-1985

Senior Scientist -Department of Molecular Biology, Genentech, Inc., 1985 - 1987

Acting Director -Department of Molecular Immunology, Genentech, Inc. 1987- 1988

Senior Scientist -Dept. of Cardiovascular Research, Genentech, Inc., 1988- 1989

Senior Scientist -Dept. of Immunobiology, Genentech, Inc., 1989-1990

Staff Scientist -Dept. of Immunobiology, Genentech, 1990-1995

Staff Scientist -Dept. of Molecular Oncology, 1995-1999  
 Member Appointments and Promotions Committee -1994-1996  
 Member Research Review Committee (the committee that oversees all of  
 research at Genentech, Inc.)-1995-2002  
 Genentech Fellow -1999-2002  
 Founding General Partner  
 Latterell Venture Partners -2002-present  
 Adjunct Professor,  
 John A. Burns School  
 Of Medicine, University  
 Of Hawaii -2003-present  
 Lecturer, Haas School  
 Of Business, U.C.  
 Berkeley -2006-present

## **PUBLICATIONS**

1. Simpson, L., Simpson, A., and Lasky, L., (1976). Kinetoplast RNA of *Leishmania, tarentolae*, *in: The Biochemistry of Parasites and Host Parasite Relationships*, H. Van den Bossche, ed.
2. Tobin, A., Selvig, S., and Lasky, L., (1978). RNA Synthesis in Avian Erythroid Cells, *Dev. Biol.*, 67, 11-22.
3. Lasky, L., Nozick, N., and Tobin, A., (1978). Few Transcribed RNAs are Translated in Avian Erythroid Cells, *Dev. Biol.*, 67, 23-39.
4. Villeponteau, B., Lasky, L., and Harary, I., (1978). Lysine-Rich Histones and the Selective Digestion of the Globin Gene in Avian Red Blood Cells, *Biochem.*, 17, 5532-5536.
5. Lasky, L., and Tobin, A., (1979). Transcriptional Regulation in Avian Erythroid Cells, *Biochem.*, 18, 1594-1598.
6. Tobin, A., Chapman, B., Hansen, D., Lasky, L., and Selvig, S., (1979). Regulation of Embryonic and Adult Hemoglobin Synthesis in Chickens, *in: Cellular and Molecular Regulation of Hemoglobin Switching*, G. Stamatoyannopoulos and A.W. Nihuis, eds.
7. Lasky, L., Lev, Z., Xin, J., Britten, R., and Davidson, E., (1980). Messenger RNA Prevalence in Sea Urchin Embryos Measured with Cloned cDNAs, *Proc. Nat. Acad. Sci.*, 77, 5317-5321.
8. Lasky, L., Lev, Z., Xin, J., Thomas, T., Lee, A., Britten, R., and Davidson, E., (1980). The Expression of Abundant and Rare mRNA Sequences During Sea Urchin Development, *in: Developmental Biology*, H. Sauer, ed.
9. Lusic, A., Golde, D., Quon, D., and Lasky, L., (1982). Translation of mRNA for Human Granulocyte-Macrophage Colony Stimulating Factor, *Nature*, 298, 75-77.
10. Berman, P., Dowbenko, D., Simonsen, C., and Lasky, L., (1983). Detection of Antibodies to Herpes Simplex Virus with a Continuous Cell Lines Expressing Cloned Glycoprotein D, *Science*, 222, 524-527.
11. Lasky, L., and Dowbenko, D., (1984). DNA Sequence Analysis of the Type-Common Glycoprotein-D Genes of Herpes Simplex Virus Types 1 and 2, *DNA*, 3, 23-29.
12. Lasky, L., Dowbenko, D., Simonsen, C., and Berman, P., (1984). Protection of Mice from Lethal Herpes Simplex Virus Infection by Vaccination with a Secreted form of Cloned Glycoprotein D, *Biotechnology*, 2, 527-532.

13. Lasky, L., Dowbenko, D., Simonsen, C., and Berman, P., (1984). Production of a Herpes Simplex Virus Subunit Vaccine by Genetically Engineered Mammalian Cell Lines, *in: Modern Approaches to Vaccines*, R. Lerner and R. Chanock, eds.
14. Berman, P., Dowbenko, D., Simonsen, C., and Lasky, L., (1984). Production of a subunit Vaccine for Herpes Simplex Virus by Mammalian cell Lines Engineered to Secrete Truncated Glycoprotein D, *in: UCLA Symposium on Herpesviruses*, F. Rapp, ed.
15. Lasky, L., and Obijeski, J., (1984). Recombinant DNA Vaccines, *in: Concepts in Viral Pathogenesis*, M. Oldstone and A. Notkins, eds.
16. Lasky, L., and Obijeski, J., (1984) The Use of Recombinant DNA Technology in Vaccine Development, *in: Medical Virology*, L. de La Maza, ed.
17. Dowbenko, D., and Lasky, L., (1984). Extensive Homology Between the Herpes Simplex Virus Type 2 Glycoprotein F Gene and the Herpes Simplex Virus Type 1 Glycoprotein C. Gene, *J. Virol.*, 52, 154-163.
18. Berman, P., Crase, D., Gregory, T., and Lasky, L., (1985). Protection of Guinea Pigs from Genital HSV-2 Infection by Vaccination with Cloned HSV-1 Glycoprotein D Produced in Mammalian Cells, *Science*, 227, 1490-1492.
19. Eisenberg, R., Long, D., Ponce de Leon, M., Matthews, J., Spear, P., Gibson, M., Berman, P., Lasky, L., Golub, E., and Cohen, G., (1985). Localization of Epitopes of Glycoprotein D of Herpes Simplex Virus Type 1, *J. Virol.*, 53, 634-644.
20. Wood, W., Gitschier, J., Lasky, L., and Lawn, R., (1985). Oligonucleotide Screening of High Complexity Gene Libraries: Base Composition Independent Hybridization in Tetramethylammonium Chloride, *Proc. Natl. Acad. Sci.*, 82, 1585-1588.
21. Patzer, E., and Lasky, L., (1985). Editorial: Use of Recombinant Mammalian Cell Lines for Vaccine Production, *VACCINE*, 2, 234-235.
22. Berman, P. and Lasky, L., (1985). Engineering Glycoproteins for Use as Pharmaceuticals, *Trends in Biotechnology*, 3, 51-53.
23. Muesing, M., Smith, D., Cabradilla, C., Lasky, L., and Capon, D., (1985). Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus, *Nature*, 313, 450-458.
24. Dowbenko, D., Bell, J., Benton, C., Groopman, J., Hung, N., Vetterlein, D., Capon, D., and Lasky, L., (1985). Bacterial Expression of the AIDS/Lymphadenopathy Retrovirus p24 Core Protein and its Use as a Diagnostic Reagent, *Proc. Natl. Acad. Sci.*, 82, 7748-7752.
25. Zarling, J., Moran, P., Burke, R., Pachl, C., Berman, P., and Lasky, L., (1986). Human T Cell Clones to Herpes Simplex Virus Recognize Cloned Glycoproteins B and D, *J. Immunol.*, 136, 4669-4673.
26. Cabradilla, C., Groopman, J., Lannigan, J., Renz, M., Lasky, L. and Capon, D., (1986). Serodiagnosis of Antibodies to the Human AIDS Retrovirus with a Bacterially Synthesized Env Polypeptide, *Bio/Technology* 4, 128-133.
27. Lasky, L., Groopman, J., Fennie, C., Benz, P., Capon, D., Dowbenko, D., Nakamura, G., Nunes, W., Renz, M. and Berman, P., (1986). Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein, *Science*, 233, 209-212.
28. Zarling, J., Moran, P., Lasky, L. and Moss, B., (1986). Herpes Simplex Virus (HSV) Specific Human T Cell Clones Recognize HSV glycoprotein D Expressed by a Recombinant Vaccinia Virus, *J. Virol.*, 59, 506-509.

29. Berman, P., Gregory, T., Dowbenko, D., Capon, D., and Lasky, L., (1986). Production of Viral Glycoproteins in Genetically Engineered Mammalian Cell Lines for Use as Vaccines Against Herpes Simplex Virus and the AIDS Retrovirus, *in* : Applied Virology.
30. Weiss, R., Clapham, P., Weber, J., Dalgleish, A., Lasky, L., and Berman, P., (1986). Variable and Conserved Antigens of Human Immunodeficiency Virus (HIV-1) *Nature*, 324, 572-575.
31. Cabradilla, C., Lanigan, J., Costigan, R., Lasky, L., Capon, D., Groopman, J. and Chen, F., (1986). Use of HTLV-III Recombinant Proteins for the serodiagnosis of Antibodies to the Human AIDS Retrovirus. *in*: Medical Virology V, eds. L.M. de la Maza and E.M. Peterson, Lawrence Erlbaum Assoc., NJ. pp.277-286.
32. Lasky, L.A., Fennie, C., Dowbenko, D., Nunes, W., and Berman, P., (1987). Expression of a secreted form of the AIDS Retrovirus Envelope in Mammalian Cells, *in*: UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 43, *in* Viruses and Human Cancer, R.C. Gallo, W. Haseltine, G. Klein, H. zur Hausen, eds.
33. Martin, S., Moss, B., Berman, P.W., Lasky, L.A. and Rouse T. B., (1987). Mechanisms of Antiviral Immunity Induced by a Vaccinia Virus Recombinant Expressing Herpes Simplex Virus Type 1 Glycoprotein D: Cytotoxic T Cells, *J.Virol.*, 61, 726-734.
34. Lasky, L., Groopman, J., Capon, D. and Berman, P., (1987). Expression of the HIV envelope in mammalian cell lines: vaccination and biological studies, *in*: Retrovirus of Human AIDS and Related Animal Diseases, Colloque Des Cent Gardes, Girard, M., Detho, G., and Vallette, L., Pasteur Vaccines, 135-159.
35. Lasky, L., Nakamura, G., Fennie, C., Smith, D., Patzer, E., Shimasaki, C., Berman, P., Gregory, T. and Capon, D., (1987). Delineation of a region of the human immunodeficiency virus gp120 glycoprotein critical for interaction with the CD4 receptor, *in* : AIDS Retrovirus, D. Bolognesi, ed.
36. Lasky, L.A., Nakamura, G., Smith, D.H., Fennie, C., Shimasaki, C., Patzer, E., Berman, P., Gregory, T. and Capon, D., (1987). Delineation of a Region of the Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Glycoprotein Critical for Interaction with the CD4 Receptor, *Cell*, 50, 965-985.
37. Eichberg, J.W., Zarling, J.M., Moran, P.A., Alter, H.J., Levy, J.A., Lasky, L.A., Gregory, T., Berman, P., Cobb, K.E., Kennedy, R.C., Chanh, T.C., and Dreesman, G.R., (1987). T Cell Responses to Human Immunodeficiency Virus (HIV) and its Recombinant Antigens in HIV Infected Chimpanzees, *J. Virol.*, 61, 3804-3808.
38. Clapham, P., Weiss, R., Dalgleish, A., Beverley, P., Sattentau, Q., Lasky, L., Berman, P., Madden, P., Axel, R., McDougal, J., (1987). HIV-1: Neutralizing Antibodies and Cellular Receptors *in*: Approaches to New Vaccines, Vaccines 87, Cold Spring Harbor Laboratory, ed. by R. Chanock, R. Lerner, F. Brown, H. Ginsberg, 174-178.
39. Torseth, J., Cohen, G., Eisenberg, R., Berman, P., Lasky, L., Cerini, G., Heilman, C., Kerwar, S., and Merigan, T., (1987). Native and Recombinant Herpes Simplex Virus Type 1 envelope Proteins Induce Human Immune T-lymphocyte Response, *J. Virol.*, 61, 1532-1539.
40. Willey, R.L., Smith, D.H., Lasky, L.A., Theodore, T.S., Capon, D.J., and Martin, M.A., (1988). *In Vitro* Mutagenesis Identifies a Site within the Envelope Gene of the Human Immunodeficiency Virus that is Critical for Infectivity, *J. Virol.* 62, 139-147.
41. Berman, P., Vogt, P.E. Gregory, T., Lasky, L.A., and Kern, E.R., (1988). Efficacy of Recombinant Glycoprotein D Subunit Vaccines on the Development of Primary, Recurrent, and Latent Genitals Type 2 Herpes Simplex Virus Infections in Guinea Pigs, *J. of Infect. Disease.* 157, 897-902.
42. Lasky, L., (1988). The production of subunit vaccines in transfected mammalian cell host systems, *in* : Immunization, Root, R., Warren, K., Griffiss, J., and Sande, M., Churchill Livingstone, 11-22.

43. Lasky, L., (1989). Current Status of the Development of an AIDS Vaccine, *CRC Reviews in Immunology*, 9 (3), 153-172.
44. Berman, P., Groopman, J., Gregory, T., Clapham, P., Weiss, R., Ferriarri, R., Riddle, L., Shimasaki, C., Lucas, C., Lasky, L., and Eichberg, J., (1988). HIV-1 Challenge of Chimpanzees Immunized with Recombinant gp120, *Proc. Natl.Acad. Sci., USA.* 85, 5200-5204.
45. Dowbenko, D., Nakamura, G., Fennie, C., Shimasaki, C., Riddle, L., Harris, R., Gregory, T., and Lasky, L., (1988). Epitope Mapping of the Human Immunodeficiency Virus Type 1 (HIV-1) gp120 with Monoclonal Antibodies, *J. Virol.*, 62, (3), 4703-4711
46. Lasky, L., (1988). editor, *Technological Advances in Vaccine Development*, UCLA Symposium on Molecular and Cellular Biology, Alan R. Liss, Inc., New York
47. Diamond, D., Sleckman, B., Gregory, T., Lasky, L., Greenstein, J., and Burakoff, S., (1988). Inhibition of CD4+ T Cell Function by the HIV Envelope Protein, gp120, *J. Immunol.*, 141, (11), 3715-3717.
48. Fennie, C., and Lasky, L., (1989). A Model for the Intracellular Folding of the Human Immunodeficiency Virus Type 1 (HIV-1) gp120, *J. Virol.*, 63, 639-646.
49. Lasky, L., Yednock, T., Singer, M., Dowbenko, D., Fennie, C., Nguyen, T., Rodriguez, H., Stachel, S., and Rosen, S., (1989). Cloning of a Lymphocyte Homing Receptor Reveals a Lectin Domain, *Cell*, 56, 1045-1055.
50. Bowen, B., Nguyen, T., and Lasky, L., (1989). Characterization of a Human Homologue of the Murine Peripheral Lymph Node Homing Receptor, *J. Cell Biol.*, 109, 421-427.
51. Rosen, S., Geoffrey, J., Lasky, L., Singer, M., Stachel, S., Stoolman, L., True, D., and Yednock, T., (1989). A Lymphocyte Homing Receptor is a Lectin, a Member of the Emerging LEC-CAM Family, *UCLA Symposium on Glycobiology*.
52. Lasky, L., (1990). From Virus to Vaccine: Recombinant Mammalian Cell Lines as Substrates for the Production of Herpes Simplex Virus Vaccines, *J. Med. Virol.*, 31(1), 59-61.
53. Lasky, L. (1990). Attenuated Organisms as Vaccines, *Encyclopedia of Immunology*, I. Roitt and P Delves, eds., Saunders Scientific Publications, London.
54. Bowen, B., Fennie, C., and Lasky, L. (1990). The Mel 14 Antibody Binds to the Lectin Domain of the Murine Peripheral Lymph Node Homing Receptor, *J. Cell Biol.*, 110, 147-153.
55. Watson, S., Imai, Y., Geoffrey, J., Fennie, C., Rosen, S.D., and Lasky, L. (1990). A Homing Receptor-IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venues, *J. Cell Biol.*, 110, 2221-2229.
56. Watson, S., Fennie, C., and Lasky, L., (1991). A Soluble Homing Receptor-IgG Chimera Inhibits Neutrophil Influx into an Inflammatory Site, *Nature*, 349, 164-167.
57. Springer, T. A. and Lasky, L. A. (1991). Sticky Sugars for Selectins. *Nature*, 349, 196-197.
58. Dowbenko, D., Diep, A., Taylor, B., Lusic, J., and Lasky, L., (1991). Characterization of the Murine Homing Receptor Gene Reveals Correspondance Between Coding Exons and Protein Structural Motifs, *Genomics*, 9, 270-277.
59. True, D., Singer, M., Lasky, L., and Rosen, S., (1991). Sialic Acid is Required for the Adhesive Activity of the Endothelial Ligand of a Lymphocyte Homing Receptor, *J. Cell Biol.*, 111, 2757-2764.
60. Lasky, L. A., (1991). The LEC-CAMs: a New Family of Adhesion Molecules Involved With Inflammation, *J. Cell. Biochem.*, 45, 139-146.

61. Imai, Y., Singer, M., Fennie, C., Lasky, L., and Rosen, S., (1991). Identification of a Carbohydrate-Based Ligand for a Lymphocyte Homing Receptor, *J. Cell Biol.*, 113, 1213-1221.
62. Lasky, L. A., and Rosen, S. (1991). The Selectins: Carbohydrate Binding Adhesion Molecules of the Immune System, in Inflammation: Basic Principles and Clinical Correlates, ed. by J. Gallin, I. Goldstein, and R. Snyderman. Raven Press., 407-419.
63. Lasky, L. A. (1991). The Homing Receptor (LEC-CAM 1): A Carbohydrate-Binding Adhesion Receptor Involved With Inflammation. in Adhesion: Its Role in Inflammatory Disease, ed by Harlan, J., and Lu, D., Stockton Press, 43-63.
64. Ley, K., Gachtgens, P., Fennie, C., Singer, M., Lasky, L. and Rosen, S. (1991). LEC-CAM 1 Mediates Leukocyte Rolling in Mesenteric Venules In Vivo, *Blood*, 77 (12), 2553-2555.
65. Watson, S., Imai, Y., Fennie, C., Geoffrey, J., Singer, M., Rosen, S., and Lasky, L. (1991). The Complement Binding-Like Domains of the Murine Homing Receptor Facilitate Lectin Activity. *J. Cell Biol.*, 115 (1), 235-243.
66. Bevilacqua, M., Butcher, E., Furie, B., Furie, B., Gallatin, M., Gimbrone, M., Harlan, J., Kishimoto, K., Lasky, L., McEver, R., Paulson, J., Rosen, S., Seed, B., Siegelman, M., Springer, T., Stoolman, L., Tedder, T., Varki, A., Wagner, D., Weissman, I., and Zimmerman, G., (1991). Selectins: A Family of Adhesion Receptors, *Cell*, 67, 233.
67. Foxall, C., Watson, S., Dowbenko, D., Fennie, C., Lasky, L., Kiso, M., Hasegawa, A., Asa, D., and Brandley, B., (1992). The Three Members of the Selectin Receptor Family Recognize a Common Carbohydrate Epitope, the Sialyl Lewis<sup>X</sup> Oligosaccharide. *J. Cell Biol.*, 117 (4), 895-902.
68. Lasky, L.A., Singer, M., Dowbenko, D., Imai, Y., Fennie, C., Henzel, W., Grimley, C., Gillett, N., Watson, S., and Rosen, S., (1992). An Endothelial Ligand for L-Selectin is a Novel Mucin-Like Molecule. *Cell*, 69, 927-938.
69. Erbe, D., Wolitzky, B., Presta, L., Norton, C., Ramos, R., Burns, D., Rumberger, J., Rao, N., Foxall, C., Brandley, B., and Lasky, L.A. (1992). Identification of an E Selectin Region Critical for Carbohydrate Recognition and Cell Adhesion. *J. Cell Biol.*, 119 (1), 215-227. (cover image)
70. Imai, Y., Lasky, L.A., and Rosen, S.D., (1992). Further Characterization of the Interaction between L-Selectin and its Endothelial Ligands. *Glycobiology* 2 (4), 373-381.
71. Lasky, L.A. (1992). Selectins: Interpreters of Cell Specific Carbohydrate Information During Inflammation. *Science*, 258, (964-969).
72. Dowbenko, D., Andalibi A., Lusic, A. J., and Lasky, L. A., (1993). Characterization and Chromosomal Localization of the Murine Gene Encoding GLYCAM 1: an Endothelial Mucin-Like Ligand for L-Selectin. *J. Biol. Chem.*, 268(6), 4525-4529.
73. Lasky, L.A., Singer, M., Dowbenko, D., Imai, Y., Fennie, C., Henzel, W., Grimley, C., Gillett, N., Watson, S., and Rosen, S., (1993). GLYCAM 1 (GLYcosylation dependant Cell Adhesion Molecule 1): A Novel Mucin-Like Adhesion Ligand for L Selectin. *Cold Spring Harbor Symposium on Quantitative Biology*. 57, 259-269.
74. Imai, Y., Lasky, L. A., and Rosen, S. (1993). Sulphation Requirement for GlyCAM-1, an Endothelial Ligand for L Selectin. *Nature*, 361, 555-557.
75. Mebius, R., Dowbenko, D., Williams, A., Fennie, C., Lasky, L. A., and Watson, S. (1993). The Expression of GlyCAM 1, an Endothelial Ligand for L Selectin, is Affected by Afferent Lymphatic Flow. *J. Immunol.*, 151(12), 6769-6776.
76. Lasky, L.A., Presta, L. G. and Erbe, D. V. (1993). Structure-Function Aspects of Selectin-Carbohydrate Interactions, in Cellular Adhesion: Molecular Definition to Therapeutic Potential, ed. by R. Christofferson, C. Hook and G. Poste, Plenum Press, N.Y., 37-53.

77. Erbe, D. and Lasky, L.A. (1993). Receptor-Immunoglobulin Chimeras, in Methods in Molecular Genetics, K. Adolph, ed., Academic Press, Vol. 2, 246-251.
78. Erbe, D., Watson, S., Presta, L., Wolitzky, B., Foxall, C., Brandley, B., and Lasky, L.A. (1993). P- and E-Selectin use Common Sites for Carbohydrate Ligand Recognition and Cell Adhesion, *J. Cell Biol.*, 120, 1227-1235.
79. Dowbenko, D., Kikuta, A., Fennie, C., Gillett, N. and Lasky, L.A.. (1993). The GlyCAM 1 Mucin is Expressed by Lactating Mammary Gland Epithelial Cells and is Present in Milk, *J. Clin. Inv.*, 92, 952-960.
80. Dowbenko, D., Watson, S. and Lasky, L.A. (1993). Cloning of a Rat Homologue of Murine GlyCAM-1 Reveals Conserved Structural Domains, *J. Biol. Chem.*, 268, 14399-14403.
81. Baumhueter, S., Singer, M., Henzel, W., Renz, M., Hemmerich, S., Rosen, S. and Lasky, L.A. (1993). Binding of L-selectin to the vascular sialomucin, CD34, *Science*, 262, 436-438.
82. Yoshida, T., Fennie, C., Lasky, L. A. and Lee, Y.C. (1994). A liquid phase binding analysis for L selectin—a strong dependency on highly clustered sulfate groups. *Eur. J. Biochem.*, 222, (2), 703-709.
83. Brandley, B. and Lasky, L.A. (1994). Antagonists of Selectin-Mediated Adhesion. in *Adv. in Pharmacology*.
84. Lasky, L.A. (1993). Chemokines: Combinatorial Mediators of Inflammation. *Current Biology*, 3(6), 366-368.
85. Lasky, L.A. (1993). P selectin: a "Roll" in Acute Inflammation. *Current Biology*, 3 (10), 680-682.
86. Baumhueter, S., Dybdal, N., Kyle, C., and Lasky, L.A. (1994). Global Vascular Expression of Murine CD34, a Sialomucin-Like Endothelial Ligand for L-Selectin. *Blood*, 84 (8), 2554-2565.
87. Lasky, L.A. (1994). Sialomucin Ligands for Selectins: a New Family of Cell Adhesion Molecules, in *Proceedings of the 24th International Symposium of the Princess Takamatsu Cancer Research Fund*, Princeton Scientific Publishing Co., 81-90.
88. Lasky, L.A. (1995). Selectin-Carbohydrate Interactions and the Initiation of the Inflammatory Response. *Ann. Rev. Biochem.*, 64, 113-139.
89. Lasky, L.A., (1995). Models of Selectin-Sialomucin Interactions, 4th International Uehara Foundation Symposium on Endothelium-Derived Factors and Vascular Functions, Elsevier Publishing Co., 233-240.
90. Lasky, L.A., (1994). A Sweet Success. *Nature Structural Biology*, 1, (3), 139-141.
91. Young, P.E., Baumhueter, S., and Lasky, L.A., (1995). The Sialomucin CD34 is Expressed on Hematopoietic Cells and Blood Vessels During Murine Development. *Blood*, 85(1), 96-105.
92. Fennie, C., Cheng, J., Dowbenko, D., Young, P., and Lasky, L.A., (1995). CD34<sup>+</sup> endothelial cell lines from murine yolk sac induce the proliferation and differentiation of CD34<sup>+</sup> yolk sac hematopoietic progenitors, *Blood*, 86, (12), 4454-4467.
93. Lasky, L.A., (1995). Cadherin structures: from sticky zippers to morphology. *Nature Structural Biology*, 2(4), 258-261.
94. Cheng, J. Baumhueter, S., Thibodeaux, H., Thomas, R., Cooper, S., Hague, N., Broxmeyer, H., Cacalano, G., Moore, M., and Lasky, L.A., (1996), Hematopoietic defects in mice lacking the sialomucin CD34, *Blood*, 87, 479-490.

95. Young, P., and Lasky, L.A. (1996), Development of the embryonic vascular system, in Tumor Angiogenesis. 333-342.
96. Wu, K., Yuan, J. and Lasky, L.A. (1996). Characterization of a novel member of the macrophage mannose receptor type C lectin family. *J. Biol. Chem.*, 271(35), 21323-21330.
97. Cheng, J., Daimaru, L., Fennie, C. and Lasky, L.A. (1996). A novel protein tyrosine phosphatase expressed in Lin<sup>lo</sup>CD34<sup>hi</sup>Sca<sup>hi</sup> hematopoietic progenitor cells. *Blood*. 88(4), 1156-1167.
98. Lasky, L.A. (1996). Hematopoiesis: Wandering progenitor cells. *Current Biology*, 10(6), 1238-1240.
99. Cheng, J., Wu, K., Armanini, M., O'Rourke, N., Dowbenko, D. and Lasky, L.A. (1997). A novel protein tyrosine phosphatase related to the homotypically adhering k and m receptors. *J. Biol. Chem.*, 272 (11): 7264-7277.
100. Spencer, S., Dowbenko, D., Cheng, J., Li, W., Brush, J., Utzig, S, Simanis, V. and Lasky, L.A. (1997). PSTPIP: a tyrosine phosphorylated cleavage furrow-associated protein which is a substrate for a PEST tyrosine phosphatase. *J. Cell Biol.*, 138 (4), 845-860.
101. Lasky, L.A. (1997). How integrins are activated. *Nature*, 390,15-17.
102. Dowbenko, D., Spencer, S., Quan, C. and Lasky, L.A. (1998). Identification of a novel polyproline recognition site in the cytoskeletal associated protein proline serine threonine phosphatase interacting protein (PSTPIP). *J. Biol. Chem.*, 273(2), 989-996.
103. Garcia-Porrero, J., Manaia, A., Lasky, L.A., Dieterlen, F. and Godin, I. (1998). Antigenic profiles of endothelial and hemopoietic lineages in murine intraembryonic hemogenic sites. *Developmental and Comparative Immunology.*, 22 (3), 303-319.
104. Wu, Y., Spencer, S., and Lasky, L.A. (1998). Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich Syndrome protein to PSTPIP, a cytoskeletal-associated protein. *J.Biol.Chem.*, 273(10), 5765-5770.
105. Ohneda, O., Fennie, C., Donahue, C., La, H., Villacorta, R., Cairns, B., and Lasky, L.A. (1998). Embryonic aorta-gonad-mesonephros region derived endothelium supports hematopoietic stem cell maintenance and differentiation . *Blood*, 92 (3), 908-919.
106. Wu, Y., Dowbenko, D. and Lasky, L.A. (1998). PSTPIP 2, a second tyrosine phosphorylated, cytoskeletal-associated protein that binds a PEST-type protein-tyrosine phosphatase. *J. Biol. Chem.*, 273 (46) , 30487-30496.
107. Donahue, C., Fennie, C., Villacorta, R., La, H., Lasky, L.A. and Ohneda, O. (1999). Multicolor immunofluorescence and flow cytometry using cascade blue to purify murine hematopoietic stem cells from fetal liver and bone marrow. *Cytometry*, 37, 60-67.
108. Angers-Loustau, A., Cote, J., Charest, A., Dowbenko, D. Spencer, S., Lasky, L.A., and Tremblay, M. (1999). Protein tyrosine phosphatase-PEST regulates focal adhesion disassembly, migration and cytokinesis in fibroblasts. *J. Cell Biol.*, 144(5), 1019-1031.
109. Wu, Y., Dowbenko, D., Spencer, S., Laura, R., Lee, James, Gu, Q. and Lasky, L.A. (2000). Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI 3, a novel membrane associated guanylate kinase. *J. Biol. Chem.* 275(28), 21477-21485.
110. Ohneda, O., Ohneda, K., Nomiyama, H., Zhong, Z. , Gold, S., Arai, F., Miyamoto, T., Taillon, B., McIndoe, R., Shimkets, R., Lewin, D., Suda, T., and Lasky, L.A. (2000). WECHÉ: a novel hematopoietic regulatory factor. *Immunity*, 12, 141-160.

111. Fuh, G., Pisabarro, M., Li, Y., Quan, C., Lasky, L. A., and Sidhu, S. (2000). Analysis of PDZ Domain-Ligand Interactions Using Carboxy-Terminal Phage Display. *J. Biol. Chem.*, 275(28), 21846-21491.
112. Oda, A., Ochs, H., Lasky, L.A., Spencer, S., Ozaki, K., Fujihara, M., Handa, M., Ikebuchi, K., and Ikeda, H. (2001). CrkL is an adaptor for Wiskott-Aldrich Syndrome protein and Syk. *Blood* 97(9):2633-2639
113. Lasky, L.A. (2000). The Nucleoskeleton: Go EAST Young Man. *Nature Cell Biology*, 2(5), 74-76.
113. Cong, F., Wu, Y., Spencer, S., Tremblay, M., Lasky, L.A. and Goff, S. (2000). Cytoskeletal protein PSTPIP directs the PEST type protein tyrosine phosphatase to the c-ABL kinase to mediate Abl dephosphorylation. *Mol. Cell*, 6, 1413-1423.
113. Wu, Y., Spencer, S., Dowbenko, D., Pisabarro, M, Dillard-Telm, L., Koeppen, H. and Lasky, L.A. (2001). PTEN 2, a golgi-associated, testis-specific homologue of the PTEN tumor suppressor lipid phosphatase. *J. Biol. Chem.* 276 (24), 21745-21753.
113. Ohneda, O., Ohneda, K., Arai, F., Lee, J., Miyamoto, T., Fukushima, Y., Dowbenko, D., Lasky, L.A. and Suda, T. (2001). ALCAM (CD166); its functional role in hematopoietic and endothelial development. *Blood.*, 98: 2134-2142.
113. Bai, Y., Ding, Y., Spencer, S., Lasky, L.A. and Bromberg, J. (2002). Regulation of the association between PSTPIP and CD2 in murine T cells. *Experimental and Molecular Pathology*, 71(2), 115-124.
113. Ross, S., Spencer, S., Lasky, L.A. and Koeppen, H. (2001). Selective expression of murine PSCA in fetal and adult tissues and the TRAMP<sup>tm</sup> model of prostate carcinogenesis. *Am. J. Path.*, 158 (3), 809-816.
113. Jean-François Côté, Ping Lin Chung, Jean-François Théberge, Maxime Hallé, Susan Spencer, Laurence A. Lasky, and Michel L. Tremblay (2002). PSTPIP is a substrate of PTP-PEST and serves as a scaffold guiding PTP-PEST toward a specific dephosphorylation of WASP, *J. Biol. Chem.*, 277, 2973-2986.
113. Li, Y., Dowbenko, D. and Lasky, L.A. (2001). *C. elegans* PIAK, a phospholipid independent kinase which activates the AKT/PKB survival kinase. *J. Biol. Chem.*, 276: 20323-20329.
113. Lawn, R. M. and Lasky, L.A. (2001). Editorial overview: the genomes are just the beginning. *Current Opinions in Pharmaceutical Biotechnology*.
113. Tang, T., Dowbenko, D., Jackson, A., Lewin, D. and Lasky, L.A. (2002). The forkhead transcription factor AFX activates apoptosis by the induction of the BCL-6 transcriptional repressor., *J. Biol. Chem.*, 277, 14255-14265.
123. Ross, S., Spencer, S., Holcomb, I., Tan, C., Hongo, J., Devaux, B., Rangell, L., Keller, G., Schow, P., Steeves, R., Lutz, R., Frantz, G., Hillan, K., Peale, F., Tobin, P., Eberhard, D., Rubin, M., Lasky, L.A., and Koeppen, H. (2002). Prostate stem cell antigen as a therapy target: tissue expression and in vivo efficacy of an immunoconjugate, *Cancer Res.*, 62, 2546-2553.
124. Laura, R., Ross, S., Koeppen, H. and Lasky, L.A. (2002), MAGI1: a widely expressed alternately spliced tight junction protein., *Exp.Cell Res.*, 242(1), 155-170. (cover image)
125. Li, Y., Dowbenko, D. and Lasky, L.A. [2002], AKT/PKB phosphorylation of p21<sup>cip1/waf1</sup> enhances protein stability and cell survival, *J. Biol. Chem.*, 277: 11352-11361.
126. Thomas, M., Laura, R., Hepner, K., Guccione, E., Sawyers, C., Lasky, L.A. and Banks, L. [2002]. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. *Oncogene*, 21(33), 5088-5096

127. Laura, R., Witt, A., Held, H., Gerstner, R., Koehler, M., Deshayes, K., Kosik, K., Sidhu, S. and Lasky, L.A. [2002]. The erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of d-catenin and ARVCF. *J. Biol. Chem.*, 277, 12906-12914.
128. Nicholas J. Skelton, Michael F. T. Koehler, Kerry Zobel, Wai Lee Wong, Sherry Yeh, M. Theresa Pisabarro, Jian Ping Yin, Melissa A. Starovasnik, L. A. Lasky, & Sachdev S. Sidhu, (2003) Origins of PDZ domain ligand specificity: structure determination and mutagenesis of the Erbin PDZ domain, *J. Biol. Chem.*, 278, 7645-7654.
129. Tang, T. and Lasky, L. A., (2003) The forkhead transcription factor FOXO 4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau independent mechanism. *J. Biol. Chem.*, 278, 30125-30135.
130. Hoke, D., Mebius, R., Dybdal, N., Dowbenko, D., Lasky, L.A., Gribling, P., Kyle, C., Baumheuter, S. and Watson, S. (1995). An immune response selectively modulates the expression of L-selectin ligands. *Curr. Biol.*, 5, 670-678.
131. Lasky, L.A., Skelton, N. and Sidhu, S. (2004). PDZ domains: intracellular mediators of carboxy-terminal protein recognition and scaffolding, in "Structure and Function of Modular Protein Domains", ed. by Caesarini, Sudhol and Yaffee. Wiley.
132. Hal E. Broxmeyer, Scott Cooper, Laurence A. Lasky and Frederik de Sauvage (2005). Identification of a massive reserve of hematopoietic progenitors in mice. *Stem Cells and Development*, 14, 105-110.
133. Yingnan Zhang, Brent Appleton, Heike A. Held, Sherry Yeh, Ping Wu, P. Jaya Kausalya, Dominic C.Y. Phua, Wai Lee Wong, Nicholas J. Skelton, Laurence A. Lasky, Walter Hunziker, Christian Wiesmann & Sachdev S. Sidhu (2006). Convergent and divergent ligand specificity amongst the PDZ domains of the LAP and ZO families. *J. Biol. Chem.*, 281, 22299-22231.
134. Lasky, L.A. (2007). Negotiating Points in Venture Capital, in *Biotechnology Venture Capital Investments: Leading VCs on Deal Terms, Valuations & Keys to Success for Investors and Management Teams*, Aspatore Books, Jan, 2007 (ISBN: 978-59622-644-9)

#### **Issued/Pending Patents**

1. Berman, P. and Lasky, L. A. (1989). Molecularly Cloned Diagnostic Product and Method of Use. U.S. patent # 4,855,224.
2. Lasky, L.A., Singer, M., Stachel, S., Rosen, S. and Yednock, T. (1992). DNA Sequence Encoding a Functional Domain of a Lymphocyte Homing Receptor. U.S. patent # 5,098,833. \*
3. Capon, D. and Lasky, L. A. (1992). Hybrid Immunoglobulins. U.S. patent # 5,116,964. \*
4. Lasky, L. A., Rosen, S., Stachel, S., Singer, M., Yednock, T. (1993). Lymphocyte Homing Receptors. U.S. patent # 5,216,131.
5. Capon, D. and Lasky, L.A. (1993). Lymphocyte Homing Receptor/Immunoglobulin Fusion Proteins. U.S. patent # 5,225,538. \*
6. Lasky, L., Imai, Y., Rosen, S., and Singer, M. (1994). DNA Sequences Encoding an L-selectin Ligand and Related Proteins. U.S. patent # 5,304,640
7. Capon, D., and Lasky, L.A. (1995). Hybrid Immunoglobulins. U.S. patent # 5,428,130. \*
8. Capon, D., and Lasky, L.A. (1995). Expression Vector Encoding Hybrid Immunoglobulins. U.S. Patent# 5,455,165. \*
9. Lasky, L., Imai, Y., Rosen, S., and Singer, M. (1996). A Ligand for L Selectin. U.S. Patent# 5,478,807

10. Capon, D., and Lasky, L.A. (1996). Recombinant DNA encoding hybrid immunoglobulins. U.S. Patent# 5,514,582. \*
11. Capon, D., and Lasky, L.A. (1996). Fusions of AIDS-related polypeptides. European Patent # 0 187 041 B1
12. Erbe, D., Lasky, L.A. and Presta, L. (1997). Selectin Variants. U.S.Patent# 5,593,882
13. Berman, P., Gregory, T., Lasky, L., and Nakamura, G. (1997). Methods and compositions for the use of HIV env polypeptides and antibodies thereto. European Patent # 02796884
14. Lasky, L.A. and Wood, W. (1997). Improved method of hybridization with oligonucleotide probes. U.S. Patent # 5,654,147
15. Lasky, L.A., Imai, Y., Rosen, S., and Singer, S. (1997). Method for purification of L-selectin ligands. U.S. Patent #5,652,343
16. Lasky, L., Rosen, S., Stachel, S., Singer, M., and Yednock, T., (1998). Lymphocyte homing receptor polypeptides. U.S. Patent# 5,840,844
17. Berman, P., Capon, D. and Lasky, L. , (1998). Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use. U.S. Patent# 5,835,978
18. Berman Phillip W. and Lasky Laurence A., (1998). Vaccines based on membrane-bound proteins and process for making them. U.S. Patent# 5,851,533
19. Cheng, J. and Lasky, Laurence A. (1999). Kappa/mu-like protein tyrosine phosphatase lambda. U.S. Patent# 5,928,887
20. Lasky, Laurence A. and Dowbenko, D. (2000). Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPS). U.S. patent # 6,040,437
21. Cheng, J. and Lasky, Laurence A. (2000). Antibodies which specifically bind to a novel k/m-like protein tyrosine phosphatase, PTPI, and hybridoma cell lines producing the same.U.S. Patent # 6,083,748
22. Cheng, J. and Lasky, Laurence A. (2000). Novel kappa/mu-like protein tyrosine phosphatase, ptp lambda. U.S. Patent # 5,976,852
23. Lasky, Laurence A. and Dowbenko, D. (2000). Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPs). U.S. Patent # 6,111,073
24. Wu, K. and Lasky, Laurence A. (2000). Type C lectins. U.S. Patent # 6,117,977
25. Cheng, J. and Lasky, Laurence A. (2001). Protein tyrosine phosphatases. U.S. Patent # 6,238,902
26. Capon, D. and Lasky, Laurence A. (2002). Hybrid Immunoglobulins. U.S. Patent # 6,406,697\*
27. Berman, P., Capon, D. and Lasky, Laurence A. (2003). Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use. U.S. Patent # 6,534,285
28. Devaux, B., Keller, G., Koeppen, H., and Lasky, Laurence A. (2004). Anti-tumor antibody compositions and methods of use, U.S. Patent # 6,824,780.
29. Capon, D. and Lasky, Laurence A. (2003). Hybrid Immunoglobulins, U.S. Patent Application #20030143220
30. Held, Heike, Lasky, Laurence A., Laura, Richard, Sidhu, Sachdev, Wong, Wai Lee and Wu, Yan (2003). Phage displayed PDZ domain ligands, U.S. Patent Application #20030148264

31. Berman, P., Capon, D. and Lasky, Laurence A. (2004), Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use. U.S. Patent Application # 20040014172
32. Lasky, Laurence A., Baumheuter, Suzanne, Rosen, Steven, Singer, Mark (2004), Inhibition of Leukocyte Adhesion, U.S. Patent Application # 20040141966
33. Devaux, B., Keller, G., Koeppen, H., Lasky, Laurence, A. (2005). Anti-tumor antibody composition and methods of use, U.S. Patent Application # 20050036942
34. Lewin, D., Shimkets, R., Lasky, Laurence A., Taillon, B., and Gold, S. (2005). Novel hematopoietic regulatory factors and methods of use thereof, U.S. Patent Application # 2005005655
35. Lasky, Laurence A. and Dowbenko., D., (2005) Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPS), U.S. Patent # 6,887,705
36. Lasky, Laurence, Stachel, S., Rosen, S., Singer, M and Yednock, T., Lymphocyte Homing Receptors, U.S. Patent Application # 20060229435

\*Licensed by Immunex (Amgen) and Biogen. Generates significant licensing revenues (~8 figures/year) for Genentech, Inc.

### **Products in Development/Clinic**

1. Herpes Simplex Virus type 2 Vaccine- In Phase III clinical development at Glaxo-Smith Kline-RIT. Successful Phase III with ~70% protection in female vaccinees (Stanberry et al. New England Journal of Medicine, 347:1652-1661, November 21, 2002).
2. HIV 1 Vaccine- In Phase III clinical development at VaxGen. No apparent efficacy (2/2003)

### **Outcomes of Company Investments**

1. Collective Pharmaceuticals-Founded: 9/2004. Sold to Medimmune, Inc. 11/2005 for \$175 MM (~3.5X up front payment, ~9.5X including total milestone payments).